A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study

Gut microflora dysbiosis affects the majority of individuals after COVID-19, contributing to both gastro-intestinal (GI) and non-GI symptoms. Natural phytochemicals have reported anti-viral properties favourable effects on inflammatory oxidative pathways, important for tissue damage post-viral pneumonia. This study involved 147 participants with symptomatic randomised receive a placebo (P) or phytochemical-rich concentrated food capsule (PC) in addition pre/probiotic lactobacillus capsule. Participants taking PC had an almost two-fold reduction mean fatigue scores compared P [p = 0.02], three-fold cough score more than double improvement overall well-being 0.02]. Two (1.5%) mild, increased bloating which they felt was attributable capsules, although GI symptoms improved 25 31 (82%) who them at baseline. Sedentary, older, previously hospitalised men statistically significantly among those given probiotic. Although some early disease would spontaneously, such rapid observed participants, been suffering average 108 days, clinically relevant welcomed, especially likely pre-existing gut dysbiosis. We are now evaluating whether this blend could also enhance antibody titres post-COVID-19 vaccination.